287421
Alzheimer's disease mortality and lost productivity among adults aged 40-64 years, 1999-2008
Methods: Number of cases; crude, age-specific, and age-adjusted mortality rates; and AD-related productivity losses were estimated. The disease burden was compared to those of other chronic conditions.
Results: From 1999-2008, a total of 7,039 AD-related deaths were identified for the 40-64 age group in the United States. The age-adjusted mortality rate remained relatively static: 0.75 per 100,000 population in 1999 (95% CI: 0.69-0.80) to 0.71 per 100,000 population in 2008 (95% CI: 0.66-0.76). Differences in mortality trends were observed by age, sex, race and ethnicity, and place of death. AD-attributable productivity losses were nearly $3.7 billion.
Conclusion: Despite common perceptions that this disease is rare among younger adults (<65), the AD burden in the 40-64 age group was not trivial during 1999-2008. These findings have policy implications in social service allocation, healthcare planning, caregiving, and end-of-life care.
Learning Areas:
Chronic disease management and preventionEpidemiology
Social and behavioral sciences
Learning Objectives:
Describe Alzheimer’s disease mortality trends for decedents aged 40-64 years using the 1999-2008 U.S. multiple-cause-of-death dataset.
Present lost productivity results for decedents with Alzheimer’s disease who belong to the 40-64 age group.
Discuss policy implications in social service allocation, healthcare planning, caregiving, and end-of-life care based on study findings.
Keyword(s): Emerging Health Issues, Dementia
Qualified on the content I am responsible for because: I am qualified to be an abstract author on this content because I am a medical student who has conducted research in this area, having published a recent peer-review article on Alzheimer's mortality.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.